Solid Biosciences (SLDB) Non-Current Deffered Revenue (2020 - 2021)

Solid Biosciences (SLDB) reported Non-Current Deffered Revenue of $2.3 million for Q3 2021, down 47.52% sequentially from $4.3 million in Q2 2021.

Solid Biosciences (SLDB) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

Solid Biosciences (SLDB) has 2 years of Non-Current Deffered Revenue data on file, last reported at $2.3 million in Q3 2021.

For the quarter ending Q3 2021, Non-Current Deffered Revenue changed N/A year-over-year to $2.3 million; the trailing twelve-month figure through Sep 2021 stood at $2.3 million (changed N/A YoY), and the FY2020 full-year result was $10.4 million, changed N/A from the prior year.
Non-Current Deffered Revenue declined to $2.3 million in Q3 2021, from $4.3 million in the prior quarter.
In the past five years, Non-Current Deffered Revenue ranged from a high of $10.4 million in Q4 2020 to a low of $2.3 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	225.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Solid Biosciences	529.40 Mn	529.40 Mn	-	-

Download Data